124 related articles for article (PubMed ID: 38417401)
1. Tabersonine Enhances Olaparib Sensitivity through FHL1-Mediated Epithelial-Mesenchymal Transition in an Ovarian Tumor.
Chen X; Yan Y; Liu Y; Yi Q; Xu Z
J Nat Prod; 2024 Apr; 87(4):837-848. PubMed ID: 38417401
[TBL] [Abstract][Full Text] [Related]
2. miR-636 inhibits EMT, cell proliferation and cell cycle of ovarian cancer by directly targeting transcription factor Gli2 involved in Hedgehog pathway.
Ma J; Zhou C; Chen X
Cancer Cell Int; 2021 Jan; 21(1):64. PubMed ID: 33472614
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib.
Liu L; Zhang Z; Zhang G; Wang T; Ma Y; Guo W
J Transl Med; 2020 Sep; 18(1):357. PubMed ID: 32951601
[TBL] [Abstract][Full Text] [Related]
4. Anti-oncogenic mechanism of KLF17 in colon cancer by repressing cell migration and invasion via FHL1 upregulation.
Yi S; Luo M; Peng Y; Chen Y; Yu D
Chin J Physiol; 2023; 66(6):534-545. PubMed ID: 38149566
[TBL] [Abstract][Full Text] [Related]
5. Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer.
Chowdhury P; Dey P; Ghosh S; Sarma A; Ghosh U
BMC Cancer; 2019 Aug; 19(1):829. PubMed ID: 31438892
[TBL] [Abstract][Full Text] [Related]
6. Possible Action of Olaparib for Preventing Invasion of Oral Squamous Cell Carcinoma In Vitro and In Vivo.
Nakamura N; Fujihara H; Kawaguchi K; Yamada H; Nakayama R; Yasukawa M; Kishi Y; Hamada Y; Masutani M
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269669
[TBL] [Abstract][Full Text] [Related]
7. The Drug Combination of SB202190 and SP600125 Significantly Inhibit the Growth and Metastasis of Olaparib-resistant Ovarian Cancer Cell.
Chen X; Chen Y; Lin X; Su S; Hou X; Zhang Q; Tian Y
Curr Pharm Biotechnol; 2018; 19(6):506-513. PubMed ID: 30003858
[TBL] [Abstract][Full Text] [Related]
8. Emodin exerts antitumor effects in ovarian cancer cell lines by preventing the development of cancer stem cells via epithelial mesenchymal transition.
Long H; Chen H; Yan J; Cheng H
Oncol Lett; 2022 Mar; 23(3):95. PubMed ID: 35154426
[TBL] [Abstract][Full Text] [Related]
9. Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib.
Roberts CM; Rojas-Alexandre M; Hanna RE; Lin ZP; Ratner ES
Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568736
[TBL] [Abstract][Full Text] [Related]
10. Bovine lactoferrin reverses programming of epithelial-to-mesenchymal transition to mesenchymal-to-epithelial transition in oral squamous cell carcinoma.
Chea C; Miyauchi M; Inubushi T; Okamoto K; Haing S; Nguyen PT; Imanaka H; Takata T
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):142-147. PubMed ID: 30415774
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II type 2 receptor-interacting protein 3a inhibits ovarian carcinoma metastasis via the extracellular HMGA2-mediated ERK/EMT pathway.
Ping H; Guo L; Xi J; Wang D
Tumour Biol; 2017 Jun; 39(6):1010428317713389. PubMed ID: 28651497
[TBL] [Abstract][Full Text] [Related]
13. Biguanides in combination with olaparib limits tumorigenesis of drug-resistant ovarian cancer cells through inhibition of Snail.
Wang Q; López-Ozuna VM; Baloch T; Bithras J; Amin O; Kessous R; Kogan L; Laskov I; Yasmeen A
Cancer Med; 2020 Feb; 9(4):1307-1320. PubMed ID: 31863638
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib.
Wang Z; Gao J; Ohno Y; Liu H; Xu C
Cancer Chemother Pharmacol; 2020 Feb; 85(2):273-284. PubMed ID: 31907647
[TBL] [Abstract][Full Text] [Related]
15. Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin.
Hugo HJ; Gunasinghe NPAD; Hollier BG; Tanaka T; Blick T; Toh A; Hill P; Gilles C; Waltham M; Thompson EW
Breast Cancer Res; 2017 Jul; 19(1):86. PubMed ID: 28750639
[TBL] [Abstract][Full Text] [Related]
16.
Chen Y; Huang L; Wang S; Li JL; Li M; Wu Y; Liu T
Cancer Manag Res; 2019; 11():2415-2424. PubMed ID: 31118763
[No Abstract] [Full Text] [Related]
17. Alteration of epithelial-mesenchymal transition markers in human normal ovaries and neoplastic ovarian cancers.
Yi BR; Kim TH; Kim YS; Choi KC
Int J Oncol; 2015 Jan; 46(1):272-80. PubMed ID: 25310727
[TBL] [Abstract][Full Text] [Related]
18. Combination treatment with cisplatin, paclitaxel and olaparib has synergistic and dose reduction potential in ovarian cancer cells.
Gao J; Wang Z; Fu J; A J; Ohno Y; Xu C
Exp Ther Med; 2021 Sep; 22(3):935. PubMed ID: 34335884
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-654-3p enhances cisplatin sensitivity by targeting QPRT and inhibiting the PI3K/AKT signaling pathway in ovarian cancer cells.
Niu YC; Tong J; Shi XF; Zhang T
Exp Ther Med; 2020 Aug; 20(2):1467-1479. PubMed ID: 32742380
[TBL] [Abstract][Full Text] [Related]
20. Tabersonine attenuates lipopolysaccharide-induced acute lung injury via suppressing TRAF6 ubiquitination.
Zhang D; Li X; Hu Y; Jiang H; Wu Y; Ding Y; Yu K; He H; Xu J; Sun L; Qian F
Biochem Pharmacol; 2018 Aug; 154():183-192. PubMed ID: 29746822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
